ND

Nathan Davis

Analyst at RA Capital Management, LLC

Greater Boston

Invests in

Stages:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Work Experience

  • Board Observer

    2021

  • Board Member

    2021

  • Board Observer

    2021

  • Analyst

    2022

    Nate Davis is an Analyst on the Investment Team at RA Capital Management. Nate conducts due diligence on biotechnology companies at RA Capital and serves as a Board Director for The Covid Apollo Project and Nucleix. Previously, Nate worked closely with the Investment Team, as a Senior Associate within the TechAtlas division, to originate conviction in potential investments by identifying breakthroughs and putting data into context. Prior to RA Capital, Nate worked as an Investment Analyst at Wolfram Ventures. Nate has a BS in Biological Sciences from University of Vermont.

  • Associate

    2019 - 2022

    I am an Associate with the TechAtlas division of RA Capital Management. My primary responsibility is to create competitive landscapes of drugs and medical devices for disease indications and capabilities.

2021 - 2023

  • Executive Chair

    2021 - 2023

2021 - 2022

  • Board Observer

    2021 - 2022

  • Board Observer

    2021 - 2022

2021 - 2021

  • Board Observer

    2021 - 2021

2018 - 2019

  • MassConnect Mentor

    2018 - 2019

2017 - 2018

  • Analyst

    2017 - 2018

    • Performed due diligence on investment candidates, including market dynamics, competitive landscape, and financial statements • Assisted potential candidates with go-to-market strategy, team creation and fundraising strategy